Back to dashboard
All PlansCoverageMedium impact

Genetic Testing for FLT3, NPM1, CEBPA, IDH1, and IDH2 Variants in Cytogenetically Normal Acute Myeloid Leukemia

Blue Cross & Blue Shield of Mississippi·MS · Hematology, Oncology·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

This policy establishes coverage criteria for genetic testing of FLT3, NPM1, CEBPA, IDH1, and IDH2 variants in patients with cytogenetically normal acute myeloid leukemia (AML). The policy provides detailed background on how these genetic markers are used for risk stratification and treatment decisions in AML patients.

Action Required

Action needed
Review this new genetic testing policy to understand coverage criteria for FLT3, NPM1, CEBPA, IDH1, and IDH2 variant testing in cytogenetically normal AML patients. Ensure billing team is familiar with the clinical indications and documentation requirements when these tests are ordered by hematology/oncology providers.

Related policy hubs